Patents by Inventor Stefanie Dimmeler
Stefanie Dimmeler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240018478Abstract: The present invention relates to a preparation method for a self-organized cardiac organoid. The invention also relates to a cardiac tissue organoid obtained by the method and to its use in regenerative medicine, as a tissue implant, or in drug screening.Type: ApplicationFiled: December 7, 2021Publication date: January 18, 2024Applicant: GENOME BIOLOGICS UGInventors: Duc Minh PHAM, Jaya KRISHNAN, Stefanie DIMMELER
-
Publication number: 20230265426Abstract: The present invention relates to a combination of inhibitory nucleic acid agents directed at a combination of miRNAs for treatment of heart failure. The combination of inhibited miRNAs comprises one of the groups selected from miR-1a, and miR-15b, or miR-1a, miR-15b and miR-27b, or miR-1a, miR-27b and miR-34a. The combinatorial inhibition of these miRNAs is shown to increase cardiomyocyte proliferation.Type: ApplicationFiled: July 23, 2021Publication date: August 24, 2023Applicant: JOHANN WOLFGANG GOETHE-UNIVERSITÄT FRANKFURTInventors: Jaya KRISHNAN, Ting YUAN, Stefanie DIMMELER
-
Publication number: 20220275336Abstract: The invention relates to a method for generating a cardiac tissue mimetic, comprising the steps of mixing cardiomyocytes (CM) and fibroblasts (FB) at a ratio from 2.5:1 to 10:1, thereby providing a first mixture, incubating said first mixture, such that said cardiomyocytes and said fibroblasts form a spherical structure, adding endothelial cells (EC) to said spherical structure at a ratio of cardiomyocytes (CM) to endothelial cells (EC) from 1.5:1 to 4:1, thereby providing a second mixture, and incubating said second mixture, such that a cardiac tissue mimetic is formed. The invention further relates to a cardiac tissue mimetic comprising cardiomyocytes (CM), endothelial cells (EC), and fibroblasts (FB), wherein said cardiac tissue mimetic comprises sarcomeric structures and vascular structures. Further aspects of the invention are the cardiac tissue mimetic for use in a method for heart tissue repair or replacement and a method for screening a compound using a cardiac tissue mimetic.Type: ApplicationFiled: July 10, 2020Publication date: September 1, 2022Applicant: GENOME BIOLOGICS UGInventors: Jaya KRISHNAN, Minh Duc PHAM, Stefanie DIMMELER
-
Publication number: 20180044672Abstract: The present invention provides novel non-coding RNAs (lncRNA) that were identified to be expressed in pericytes upon hypoxia. The lncRNA of the invention positively affect Platelet-derived Growth Factor Receptor (PDGFR) beta expression, pericytes proliferation and pericyte recruitment to endothelial cells. The invention provides inhibitors of the lncRNA for use in the treatment of diseases mediated by PDGFR expression. For example the invention described antisense approaches to target the lncRNA of the invention. Furthermore, the invention provides lncRNA inhibitors as amplifier of therapeutic PDGFR inhibitors such as imatinib or other tyrosine kinase inhibitors. lncRNA inhibitors and methods for screening modulators of lncRNA expression and/or function are provided.Type: ApplicationFiled: March 18, 2016Publication date: February 15, 2018Inventors: Christoph Michael Zehendner, Stefanie Dimmeler, Andreas Zeiher
-
Publication number: 20180023079Abstract: The present invention associates multiple circular (circRNA) with key functions of endothelial cells. The present invention provides circRNA transcripts that are correlated with cardiovascular diseases, in particular acute myocardial infarction. The circRNA of the invention therefore serve as biomarkers in the diagnosis of cardiovascular disorders. The invention provides the new nucleic acid molecules as well as diagnostic kits and compositions comprising the nucleic acids. Modulation of the expression of the circRNA of the invention further leads to endothelial cell sprouting, and therefore is applied as a treatment for cardiovascular diseases or pathological angiogenesis. The invention provides therapeutic agents modulating circRNA expression or function. Further aspects of the invention provide novel circRNA for the treatment of inflammatory diseases.Type: ApplicationFiled: February 3, 2016Publication date: January 25, 2018Inventors: Stefanie DIMMELER, Nicolas JAÉ, Niels BOECKEL, Andreas M. ZEIHER
-
Publication number: 20180023080Abstract: The present invention associates multiplelong non-coding RNA (lncRNA) with key functions of endothelial cells. The lncRNA of the present invention are therefore useful as novel drug targets for the manufacturing of medicines for the treatment of cardiovascular diseases or pathological angiogenesis in context of proliferative diseases such as cancer. Modulation of the function or expression of the lncRNA of invention can induce or repress angiogenesis and vessel growth or repair in endothelial cells. Provided are further methods for the modulation of endothelial cell functions in vitro, for example, in the context of tissue engineering.Type: ApplicationFiled: February 3, 2016Publication date: January 25, 2018Inventors: Stefanie DIMMELER, Reinier BOON, Nicolas JAÉ, Katharina MICHALIK
-
Patent number: 9862949Abstract: The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.Type: GrantFiled: February 10, 2016Date of Patent: January 9, 2018Assignee: T2CURE GMBHInventors: Stefanie Dimmeler, Andreas M. Zeiher, Angelika Bonauer, Carmen Urbich
-
Publication number: 20160237433Abstract: The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.Type: ApplicationFiled: February 10, 2016Publication date: August 18, 2016Inventors: Stefanie DIMMELER, Andreas M. ZEIHER, Angelika BONAUER, Carmen URBICH
-
Patent number: 9279123Abstract: The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.Type: GrantFiled: July 31, 2014Date of Patent: March 8, 2016Assignee: T2CURE GMBHInventors: Stefanie Dimmeler, Andreas M. Zeiher, Angelika Bonauer, Carmen Urbich
-
Patent number: 9062307Abstract: The present invention relates to antagonists of the expression and/or the function of the micro RNA miRNA-29 for use in the prevention and/or treatment of aortic aneurysms. Further disclosed is a method for the identification of miRNA-29 antagonists, a pharmaceutical composition comprising said miRNA-29 antagonists and a method for preventing and treating age-related aortic aneurysm formation in a subject in need of such a treatment.Type: GrantFiled: April 1, 2011Date of Patent: June 23, 2015Assignee: Johann Wolfgang Goethe-Universität Frankfurt am MainInventors: Andreas Zeiher, Stefanie Dimmeler, Reinier Boon
-
Patent number: 9060915Abstract: Improving cell therapy and tissue regeneration in a patient suffering from a cardiovascular or a neurological disease by treating a tissue of the patient with shock waves and/or applying to the patient a therapeutically effective amount of stem cells and/or progenitor cells. Such treatment increases expression of chemoattractants, pro-angiogenic factors, and pro-survival factors. The chemoattractants can be, for example, vascular endothelial growth factor (VEGF) or stromal cell derived factor 1 (SDF-1). For example, the treated tissue can be located in the patient's heart or in a skeletal muscle of the patient, and the shock waves can be extracorporeal shock waves (ESW) or intracorporeal shock waves. The cardiovascular disease can have an ischemic or non-ischemic etiology. For example, the cardiovascular disease can be a myocardial infarction, ischemic cardiomyopathy, or a dilatative cardiomyopathy. For example, the neurological disease can be a peripheral neuropathy or neuropathic pain.Type: GrantFiled: June 20, 2008Date of Patent: June 23, 2015Assignee: Dornier MedTech Systems, GmbHInventors: Andreas Lutz, Harald Eizenhofer, Andreas Michael Zeiher, Stefanie Dimmeler, Christopher Heeschen, Alexandra Aicher
-
Publication number: 20150018407Abstract: The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.Type: ApplicationFiled: July 31, 2014Publication date: January 15, 2015Inventors: Stefanie DIMMELER, Andreas M. ZEIHER, Angelika BONAUER, Carmen URBICH
-
Patent number: 8912158Abstract: The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.Type: GrantFiled: August 8, 2012Date of Patent: December 16, 2014Assignee: t2cure GmbHInventors: Stefanie Dimmeler, Andreas M. Zeiher, Angelika Bonauer, Carmen Urbich
-
Patent number: 8871731Abstract: The present invention relates to treating or preventing age-related cardiomyopathy by modulating the expression or activity of a miR-34 family member and/or PNUTS. Methods of treating or preventing age-related cardiomyopathy include administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity. Also provided herein are methods of treating or preventing cardiac fibrosis and myocardial infarction by administering an inhibitor of miR-34 expression or activity or an agonist of PNUTS expression or activity.Type: GrantFiled: March 16, 2012Date of Patent: October 28, 2014Assignee: Migagen Therapeutics, Inc.Inventors: Stefanie Dimmeler, Reinier A. Boon, Ariane Fischer, Andreas M. Zeiher
-
Patent number: 8673581Abstract: The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis.Type: GrantFiled: September 13, 2012Date of Patent: March 18, 2014Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Andreas M. Zeiher, Christopher Heeschen, Stefanie Dimmeler, Christian Hamm
-
Publication number: 20130116303Abstract: The present invention relates to antagonists of the expression and/or the function of the micro RNA miRNA-29 for use in the prevention and/or treatment of aortic aneurysms. Further disclosed is a method for the identification of miRNA-29 antagonists, a pharmaceutical composition comprising said miRNA-29 antagonists and a method for preventing and treating age-related aortic aneurysm formation in a subject in need of such a treatment.Type: ApplicationFiled: April 1, 2011Publication date: May 9, 2013Applicant: Johann Wolfgang Goethe-Universitat Frankfurt am MainInventors: Andreas Zeiher, Stefanie Dimmeler, Reinier Boon
-
Patent number: 8409815Abstract: The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis.Type: GrantFiled: November 10, 2003Date of Patent: April 2, 2013Assignee: Siemens Healthcare Diagnostics Products GmbHInventors: Andreas M. Zeiher, Christopher Heeschen, Stefanie Dimmeler, Christian Hamm
-
Publication number: 20130004487Abstract: The invention relates to novel markers of vascular inflammation and combinations thereof as diagnostic and prognostic tools in patients with cardiovascular diseases. The markers also act as tools that facilitate the selection of active ingredients for the treatment of such diseases, and finally act as starting points for the treatment of cardiovascular diseases. Furthermore, the invention relates to the creation of an individual risk profile of negative events that are associated with the progression of arteriosclerosis.Type: ApplicationFiled: September 13, 2012Publication date: January 3, 2013Inventors: Andreas M. Zeiher, Christopher Heeschen, Stefanie Dimmeler, Christian Hamm
-
Publication number: 20120322856Abstract: The invention relates to a method for influencing the miR-92 expression in a cell, comprising the following steps: (a) providing a cell; and (b1) reducing the miR-92 expression in the cell in order to promote the vascularization or vessel repair by introducing an antisense molecule against miR-92 into the cell, or (b2) increasing the miR-92 expression in the cell for an inhibition of the tumor angiogenesis by introducing a construct into the cell, wherein said construct includes an expressible miR-92 sequence. Furthermore, the invention relates to a pharmaceutical composition, comprising an agent for reducing the miR-92 activity or expression in a cell in the form of an antisense molecule against miR-92, or an agent for increasing the miR-92 expression in a cell in the form of a construct for expressing miR-92.Type: ApplicationFiled: August 8, 2012Publication date: December 20, 2012Inventors: Stefanie Dimmeler, Andreas M. Zeiher, Angelika Bonauer, Carmen Urbich
-
Patent number: 8309608Abstract: The present invention relates to the use of compounds which enhance the transcription of endothelial nitric oxide synthase (eNOS) for treating stem and progenitor cells in the cell therapy of patients with ischemic heart diseases such as coronary heart disease or ischemic cardiomyopathy. Treatment of such cells which are isolated from bone marrow, for example, with an eNOS transcription enhancer prior to their administration improves their functional activity and ameliorates neovascularization of the heart and cardiac regeneration.Type: GrantFiled: November 2, 2004Date of Patent: November 13, 2012Assignee: Sanofi-Aventis Deutschland GmbHInventors: Andreas Zeiher, Stefanie Dimmeler, Christopher Heeschen, Hartmut Ruetten